Peptides for perimenopause: what the science actually supports

What did @daniellesandersca actually say?

Honestly, not much. The transcript captured here is essentially a false start: "I'll take my whiskey, need my coffee, bla- Your take." That is the entirety of what was recorded. The caption fills in more context, describing perimenopause as a moment when "what used to work, just doesn't anymore" and framing peptides as a reasonable response to that shift. So we are fact-checking a caption and a category, not a fully delivered argument.

That matters. A lot of peptide content on TikTok trades on the authority of the creator's personal story without making specific, falsifiable claims. This video appears to follow that pattern. The caption sets up a relatable narrative, eating well, moving her body, doing the "right things," and implies peptides filled a gap. What gap? Which peptides? At what point? Those details are absent, which makes this harder to fact-check and easier to believe uncritically.

Does the science back this up?

The general premise, that hormonal changes in perimenopause alter metabolism, recovery, and body composition in ways that make previous strategies less effective, is well supported. The peptide claims, however, exist in a much murkier space.

Perimenopause involves declining estrogen and progesterone, with downstream effects on insulin sensitivity, muscle protein synthesis, and sleep architecture. Freeman et al. (2014, Menopause) documented that perimenopausal women experience significant changes in body composition independent of caloric intake. So "doing the right things" and still struggling is a real, documented phenomenon, not a marketing narrative.

Peptides are a different story. The category named in this video's tags includes BPC-157, CJC-1295, ipamorelin, GHK-Cu, and MK-677. Most of these have limited or no published human clinical trial data. BPC-157 has promising animal studies (Sikiric et al., 2018, Current Pharmaceutical Design) but no completed randomized controlled trials in humans. MK-677 is a ghrelin mimetic that has been studied in older adults for muscle mass, but it also raises IGF-1, which carries long-term cancer risk signals (Nass et al., 2008, Journal of Clinical Endocrinology and Metabolism). The science does not cleanly back up the implied narrative here.

What did they get wrong (or right)?

Credit where it is due: framing perimenopause as a physiological inflection point, not just a vibe shift, is accurate. Hormonal transitions genuinely do change the rules for recovery, sleep, and body composition. That part holds up.

What is missing, and this is a real problem, is any acknowledgment that the peptide category itself is not monolithic. Lumping BPC-157, semax, selank, and MK-677 into a general "they work for perimenopause" framing glosses over enormous differences in mechanism, risk profile, and evidence base. Semax is a neuropeptide with some cognitive research behind it (Dolotov et al., 2006, Journal of Neurochemistry). MK-677 manipulates growth hormone secretion systemically. These are not the same category of intervention just because they share a label.

The video also gestures toward a "I tried everything else" narrative without specifying whether conventional options, specifically hormone replacement therapy, were considered or tried. HRT has a strong and growing evidence base for perimenopausal symptoms (Manson et al., 2017, New England Journal of Medicine). Presenting peptides as an alternative without that context is an omission that can mislead people.

What should you actually know?

Perimenopause is real, the hormonal changes are documented, and yes, standard lifestyle advice often underperforms during this transition. That does not mean peptides are the answer. Most peptides promoted in this space are either compounded, research-grade, or both. Compounded peptides are not FDA-approved drugs. Quality, purity, and dosing are not standardized across suppliers.

If you are in perimenopause and feeling like your body is not responding the way it used to, the most evidence-supported first step is a conversation with a clinician about hormonal status, not a peptide protocol built from TikTok content. HRT, when appropriate, has decades of safety data being actively reanalyzed and updated. Most peptides in this category do not.

Some peptides may eventually prove useful as adjunct therapies. That research is ongoing. But "may eventually prove useful" and "is proven to work for perimenopausal women" are very different statements, and the gap between them is where a lot of this content lives.

• Peptides vary enormously in mechanism, risk, and evidence quality.
• No peptide in this video's category has FDA approval for perimenopausal symptoms.
• The perimenopausal physiology framing is accurate. The peptide solution framing is not established.
• HRT remains the most evidence-supported intervention for perimenopausal hormonal symptoms.